by the numbers

Houston ranked a top market for attracting funding for sustainability-focused startups

According to a new report, Houston is one of the top cities for funding for sustainability companies. Photo via Getty Images

From a financial standpoint, Houston appears to be a sustainable environment for sustainability-focused startups.

An analysis by PromoLeaf, a retailer of sustainable promotional products, finds that Houston ranks fourth among U.S. cities for the average funding raised by locally based startups in the sustainability sector, according to Crunchbase data.

Per the report, the Bayou City attracts $150.7 million in sustainability funding for startups. Ahead of Houston are Salt Lake City with $204.5 million; Santa Monica, California, with $154.3 million; and Fremont, California, with $153.4 million.

PromoLeaf’s analysis features cities where at least 20 companies are focused on sustainability.

The analysis indicates Houston has 20.6 sustainability startups per 100,000 residents. Ranking first in that regard is Boulder, Colorado (115 per 100,000 residents).

While Houston trails Boulder by a long distance, it fares well among the Texas cities in the analysis:

  1. Austin, 26.2 sustainability startups per 100,000 residents
  2. Houston, 20.6 sustainability startups per 100,000 residents
  3. Midland, 18.8 sustainability startups per 100,000 residents
  4. Plano, 11.9 sustainability startups per 100,000 residents
  5. Dallas, 11 sustainability startups per 100,000 residents
  6. Fort Worth, 5.3 sustainability startups per 100,000 residents
  7. San Antonio, 5.2 sustainability startups per 100,000 residents

PromoLeaf says more than 21,600 sustainability startups operate in the U.S. They’re in the renewable energy, recycling and pollution control, environmental engineering, green consumer goods, and environmental consulting industries.

The analysis shows Houston has:

  • 13.7 renewable energy startups per 100,000 residents
  • 5.8 recycling and pollution control startups per 100,000 residents
  • 3.5 environmental engineering startups per 100,000 residents
  • 2.9 environmental consulting startups per 100,000 residents
  • 0.70 green consumer goods startups per 100,000 residents

According to the Greater Houston Partnership, renewable energy startups leading Houston’s energy transformation include Energy Transition Ventures, Fysikes Biosolutions, Ionada, Katz Water Technologies, Pressure Corp., and Renewell Energy.

“A dynamic business climate combined with growth in venture capital funding in Houston has created fertile ground for companies of all stages aiming to power our world through the global energy transition,” the partnership says. “As the Energy Capital of the World, Houston has become a hub for startups and venture capital firms investing in the region’s energy future.”

Outside the energy sector, Houston startups like Trendy Seconds also are making their mark in sustainability. The company runs an online marketplace where women can find preowned clothing or shop for new clothing from sustainable brands.

“Our ultimate goal is to make responsible consumption super easy,” Maria Burgos, founder of Trendy Seconds, told InnovationMap last year.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted